17,261 trials
Non-small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 8.16 months
Lymphangioleiomyomatosis
Primary: Change From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations — -464.3; -1113.2; -1771.7 pg/mL
Alzheimer's Disease
Primary: Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) Score at Baseline — 21.87; 22.66 units on a scale
Chronic Plaque Psoriasis
Primary: Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12 — 0; 46.2; 67.4; 75.0…
Diabetes Mellitus Type 2
Primary: Absolute Change in HbA1c — 7.872; 7.939; 8.006; 7.998 Percentage
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
Ovarian Cancer Stage IIIC · Ovarian Cancer Stage IV
Primary: Best Overall Response and Objective Response Rate Following Treatment With CS-1008 in Combination With Chemotherapy (Paclitaxel/Carboplatin) in Locally Advanced or…
Breast Cancer
Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants
Alzheimer's Disease
Primary: Change From Baseline (Day 1) in Global and Regional Indices of Cerebral Metabolic Rate of Glucose (CMRglu) at Month 12 — -0.2793; -0.0887; -0.3143; -0.0786 Milligrams…
Hemophagocytic Syndrome (HPS)
Primary: Overall Survival at 2 Months — 6 Participants
Prostate Cancer Metastatic
Primary: Number of Participants With Treatment Emergent Adverse Events — 1; 4; 2; 0 Participants
Diabetic Macular Edema
Primary: Mean Change in Vision at 24 Months — 72.5; 75.0; 75.0 units on a scale
Head and Neck Cancer · Free Tissue Transfer
Primary: Post-Operative Pain at Donor-Site — 52.40; 41.14; 41.00; 40.88 score on a scale
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 12 — 44.2; 56.1; 63.5; 68.6 percentage of participants — p=0.1236
Acne Vulgaris
Primary: Change in HPA Axis Response to Cosyntropin — 17.0; 16.8; 27.7; 24.6 mcg/dL